Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

Keyphrases

• Overall Survival 100%
• Pembrolizumab 100%
• Renal Cell Carcinoma 100%
• Placebo 54%
• After Surgery 27%
• Disease-free Survival 27%
• Confidence Interval 18%
• Hazard Ratio 18%
• Clear Cell Renal Cell Carcinoma (ccRCC) 18%
• Merck 18%
• Adverse Events 9%
• High Incidence 9%
• Toxic Effects 9%
• Interim Analysis 9%
• Survival Benefit 9%
• Placebo Groups 9%
• Serious Adverse Events 9%
• Withdrawal of Consent 9%
• Clinically Meaningful Improvement 9%
• Recurrence Risk 9%
• Double-blind Placebo-controlled Trial 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Overall Survival 100%
• Pembrolizumab 100%
• Renal Cell Carcinoma 100%
• Placebo 72%
• Recurrent Disease 36%
• Disease Free Survival 27%
• Adverse Event 18%
• Toxicity 9%